"Lebrikizumab Clears Eczema Skin Rapidly, Safely" - Kevin Kunzmann
Novel monoclonal antibody lebrikizumab was shown to significantly benefit adults with moderate to severe atopic dermatitis (eczema) in new phase 2b data evidencing the interleukin 13 (IL-13)-targeting therapy.

Press Release
Mount Sinai Experts Author Landmark ‘Seminar’ on Atopic Dermatitis (Eczema) in The Lancet
Feb 13, 2025 View All Press Releases